Breast Cancer Clinical Trial
Official title:
CAMISS Retrospective Cohort - Effect of Interval Cancer and Screening Process on Survival and Disease-free Period in Breast Cancer
This is a multicenter retrospective cohort of women participating in breast cancer screening
programs in Spain between 2000 and 2009, with a cancer diagnosed during the screening or
between the screening interval (interval cancer), specifically true interval cancers and
false negatives. The investigators obtained woman-related information (including breast
density), tumor-related information (including tumor phenotype), and follow-up information
(including relapses, second neoplasms and vital status at the end of follow up (June 2014)).
The objective is to evaluate the survival and disease-free period of women participating in
screening programs for breast cancer with a cancer diagnosed during the screening or an
interval cancer, specifically true interval cancers and false negatives.
This study is part of a broader project (CAMISS study), which also includes one prospective
cohort (CAMISS Prospective cohort - Identifier in ClinicalTrials.gov: NCT02439554).
The general objective for this study is to evaluate the survival and disease-free period of
women participating in screening programs for breast cancer with a cancer diagnosed during
the screening or an interval cancer, specifically true interval cancers and false negatives.
The cohort has information of women participating in breast cancer screening programs in
Spain between 2000 and 2009, with a breast cancer diagnosed during the screening or between
the screening interval (interval cancer), specifically true interval cancers and false
negatives. The investigators obtained woman-related information (including breast density),
tumor-related information (including tumor phenotype), and follow-up information (including
relapses, second neoplasms and vital status at the end of follow up (June 2014)).
Expected results: Nowadays there are no results of cohort analysis of the diagnostic process
of care that integrates all those different aspects. This study will complement the
evaluation of population screening, specifically the interval cancer and the impact on
survival and disease-free period taking into account relevant variables like breast density,
tumor phenotype, clinical complications, readmissions, and the surgical approach.
This study is part of a broader project (CAMISS study) coordinated by the Evaluation of
Health Services of Epidemiology and Public Health Group, which consists of two cohorts of
women diagnosed with breast cancer: a prospective cohort (n=2,040 incident cases of breast
cancer diagnosed in 18 hospitals of 5 Spanish regions) (Identifier in ClinicalTrials.gov:
NCT02439554) and a retrospective cohort of screened women diagnosed with breast cancer
between 2000 and 2009 in two Spanish regions (n=1,086).
The general objective of the CAMISS study is to evaluate different aspects of health care
received by patients with breast cancer like the diagnostic process, treatment,
complications, survival, costs and quality of life to provide information to improve the
effectiveness and cost-effectiveness of interventions, reduce variability, have better
predictive rules and increase the quality of life.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |